Navigation Links
NOVAVAX, Inc. Receives NASDAQ Non-Compliance Letter
Date:2/18/2010

ROCKVILLE, Md., Feb. 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it received a notice of deficiency, as expected, from the NASDAQ Stock Market (NASDAQ) listing qualifications department.  As a result of the election of Stanley C. Erck as the Executive Chairman Novavax is no longer in compliance with the NASDAQ requirement set forth in Listing Rule 5605(b)(1), which requires that the company's Board of Directors be comprised of a majority of independent directors.

Novavax has 45 days to submit a plan to NASDAQ to regain compliance.  The notification has no immediate effect on the listing of Novavax's common stock on The NASDAQ Global Market. The Company's common stock continues to trade on The NASDAQ Global Market under the symbol "NVAX".

Over recent months, the Nominating and Corporate Governance Committee of Novavax's Board of Directors has been identifying, evaluating and recruiting potential candidates for election to the Board of Directors.  Novavax expects to elect two independent directors and thus cure this non-compliance before its 2010 Annual Meeting of Stockholders.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.  The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches.  Novavax is committed to using its VLP technology to create country-specific vaccine solutions.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

Forward Looking Statements

Statements herein relating to future performance, conditions or strategies and other business matters, including expectations regarding the timing of curing the non-compliance with Nasdaq Listing Rule 5605(b)(1) are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including Novavax's ability to attract qualified individuals to serve on its Board of Directors, the cash and equity compensation such individuals might require to serve on the Board of Directors, and the timing of such elections.  Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this Current Report on Form 8-K.

SOURCE Novavax, Inc.

Back to top

RELATED LINKS
http://www.novavax.com

'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The ... consultations to communities in the greater Denver region, is announcing a charity drive ... a very rare kind of epilepsy. , Until a few months ago, Dominik ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen ... services to communities in the greater Birmingham area, is joining the Chris Hammond ... young people in the region. , The Chris Hammond Youth Foundation maintains athletic ...
(Date:7/21/2017)... PHILADELPHIA (PRWEB) , ... July 21, 2017 , ... ... ARTZ Philadelphia and Theater of Witness , was awarded a $300,000 ... growing humanities program which fosters empathy, comfort with ambiguity and the recognition of ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” ... plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... medical students improve their chances of acceptance to a residency in a United ... have earned degrees outside the U.S. , According to data released by the ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... Md. , July 13, 2017  New York City-based ... of pharmaceutical markets should be aware of.  From new products ... trends are detailed in a recently completed study, Potential ... 1.  Age-Driven Growth ... we have been aware of the impact the growing population ...
(Date:7/11/2017)...  Bayer has awarded grants totaling more than $2 million ... prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and ... and Uniformed Services University of the Health Sciences in ... recipients were announced last night during a reception at the ... Berlin, Germany . ...
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
Breaking Medicine Technology: